Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

The clearance broadens use of Omvoh, which is part of a slate of new medicines Lilly is counting on to build on its success ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

For the past year, Jonsson has run Lilly Diabetes and Obesity, which means he oversees everything from insulin shots to the newer, high-demand drugs now known as "weight-loss" shots: Mounjaro ...